1. Impact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry.
- Author
-
Duarte, Fernando Barroso, Moura, Anna Thawanny Gadelha, Funke, Vaneuza Araújo Moreira, Colturato, Virgílio Antônio Rensi, Hamerschlak, Nelson, Vilela, Neysimélia Costa, Lopes, Luiz Fernando, de Almeida Macedo, Maria Cristina Martins, Vigorito, Afonso Celso, de Almeida Soares, Rodolfo Daniel, Paz, Alessandra, Stevenazzi, Mariana, Diaz, Lilián, Neto, Abrahao Elias Hallack, Bettarello, Gustavo, de Gusmão, Breno Moreno, Salvino, Marco Aurélio, Calixto, Rodolfo Froes, Moreira, Maria Cláudia Rodrigues, and Teixeira, Gustavo Machado
- Subjects
- *
STEM cell transplantation , *MYELODYSPLASTIC syndromes , *HEMATOPOIETIC stem cell transplantation , *BONE marrow , *HEMATOPOIETIC stem cells , *TRANSPLANTATION of organs, tissues, etc. - Abstract
• In pre-hematopoietic stem cell transplantation (HSCT) treated and untreated patients, there is no difference in survival. • The type of pre-HSCT treatment has a significant difference in overall survival. • Hypomethylating agents and chemotherapy in pre-HSCT treatment improve myelodysplastic syndrome survival. It has been suggested that bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) can be valuable in the treatment of patients with myelodysplastic syndromes (MDS). However, the influence of this approach on HSCT outcomes remains poorly defined. Therefore, our objective was to investigate the influence of treatment before HSCT in patients with MDS. We retrospectively analyzed data from the Latin American registry of 258 patients from 17 Latin American centers who underwent HSCT from 1988 to 2019. Our data showed that there was pre-HSCT. We detected no significant difference regarding the impact on overall survival of treated and untreated patients before HSCT. Despite these data, the type of previous treatment among treated patients showed a significant difference in overall survival. Treatment with hypomethylating agents together with pre-HSCT chemotherapy seems to result in better survival of the studied population. These data correspond to the first results obtained through cooperative work between various centers in Latin America comparing the different approaches to patients and reflecting their reality and challenges. Therefore, the selection of pretransplant bridge therapy should be analyzed and focus given primarily to those approaches that result in better survival of patients with MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF